Imlunestrant vs Palazestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Imlunestrant · Inluriyo

Marketed by Eli Lilly

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04975308 · Phase 3 · active, not recruiting

EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.

Next expected readout: October 2028 · NCT07905001 (registry estimate)

Reported efficacy

Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)

Result source: NCT04975308

Palazestrant

Developed by Olema Pharmaceuticals, Inc.

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Weak signal

NCT04505826 · Phase 1/2 · completed

The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.

Next expected readout: December 2027 · NCT05508906 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointImlunestrantPalazestrant
PFS, median5.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results
—Trial running · NCT06016738
OS, median—Trial running · NCT04975308—Trial running · NCT06016738
ORR10.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
—Trial running · NCT06016738
Clinical benefit rate46.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
—Trial running · NCT06016738

PFS, median

Imlunestrant
5.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results
Palazestrant
—Trial running · NCT06016738

OS, median

Imlunestrant
—Trial running · NCT04975308
Palazestrant
—Trial running · NCT06016738

ORR

Imlunestrant
10.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
Palazestrant
—Trial running · NCT06016738

Clinical benefit rate

Imlunestrant
46.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
Palazestrant
—Trial running · NCT06016738
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Imlunestrant: 4 of 4 rows · Palazestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricImlunestrantPalazestrant
Dropout rate
25.7%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
45.1%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
0%300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
0%210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
0%150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
0%120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
0%90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
Discontinued due to AEs
3%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5.6%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Serious AEs
14.1%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
20.2%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
28.6%300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
28.6%210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
40%150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
19.3%120 mg QD
NCT04505826 · Phase 1/2
57.1%120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
33.3%90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
12.1%60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Most frequent reported AEs
diarrhoea 21.7%
nausea 18%
arthralgia 15.3%
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 86.5%
nausea 50%
anaemia 43.8%
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
300 mg QDa
nausea 85.7%
vomiting 71.4%
fatigue 57.1%
NCT04505826 · Phase 1/2
show 7 more results
210 mg QD
constipation 57.1%
nausea 57.1%
decreased appetite 42.9%
NCT04505826 · Phase 1/2
150 mg QD
nausea 80%
neutrophil count decreased 40%
vomiting 40%
NCT04505826 · Phase 1/2
120 mg QD
nausea 66.3%
fatigue 28.9%
vomiting 28.9%
NCT04505826 · Phase 1/2
120 mg QD
constipation 42.9%
hypokalaemia 42.9%
nausea 42.9%
NCT04505826 · Phase 1/2
90 mg QD
anxiety 33.3%
nausea 33.3%
photopsia 33.3%
NCT04505826 · Phase 1/2
60 mg QD
nausea 42.4%
fatigue 39.4%
headache 21.2%
NCT04505826 · Phase 1/2
30 mg QD
constipation 40%
diarrhoea 40%
fatigue 40%
NCT04505826 · Phase 1/2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Imlunestrant

PFS 5.55 vs 5.52 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS 9.36 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
14.52 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 10.3% (n=331) vs 6.4% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
11.6% (n=138) vs 5.9% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 46.8% (n=331) vs 45.5% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
46.4% (n=138) vs 36.4% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 21.1% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
9.4% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.07 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 62.9% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
44.1% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Palazestrant

ORR 0% (n=4)300 mg QD
event count · % of participants
No placebo or comparator arm
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
show 7 more results
0% (n=4)*210 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=1)*150 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
6.5% (n=62)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 4 Participants as posted
0% (n=5)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=4)*90 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
7.1% (n=28)*60 mg QD
NCT04505826 · Phase 1/2 · converted to % from 2 Participants as posted
0% (n=5)*30 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Imlunestrant's landscape · Palazestrant's landscape